2月6日，渤健（Biogen）公布2025年第四季度及全年业绩，整体销售额下滑7%至23亿美元，下滑主要因多发性硬化症 (MS) Tecfidera（富马酸二甲酯）面临仿制药竞争后销售额暴跌51%。虽然大部分MS产品持续面临压力，Vumerity（diroximel fumarate）有望成为未来增长线。阿尔茨海默病药物Leqembi皮下注射制剂Q4销售额增长了 54%，达到 1.34 亿美元。...
Source Link2月6日，渤健（Biogen）公布2025年第四季度及全年业绩，整体销售额下滑7%至23亿美元，下滑主要因多发性硬化症 (MS) Tecfidera（富马酸二甲酯）面临仿制药竞争后销售额暴跌51%。虽然大部分MS产品持续面临压力，Vumerity（diroximel fumarate）有望成为未来增长线。阿尔茨海默病药物Leqembi皮下注射制剂Q4销售额增长了 54%，达到 1.34 亿美元。...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.